BIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a report published on Monday morning. The firm issued a sell rating on the medical technology company’s stock.

Several other analysts also recently commented on BIOL. Benchmark reaffirmed a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a report on Wednesday, October 2nd. Ascendiant Capital Markets decreased their price target on BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd.

BIOLASE Price Performance

BIOL opened at $0.01 on Monday. BIOLASE has a 1 year low of $0.02 and a 1 year high of $1.94. The business’s 50-day moving average is $0.01 and its two-hundred day moving average is $0.04. The firm has a market capitalization of $367,477.00, a PE ratio of 0.00 and a beta of 0.67.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.